Journal of Oncology Pharmacy Practice最新文献

{"title":"CyFRASS-TR: A practical clinical predictive model for acute irinotecan-induced toxicity to enhance patient safety in solid tumor management.","authors":"Natharin Phattayanon, Assawin Dadookel, Nopphadol Nuntamool, Panudda Dechwongya, Teerapong Nampuan, Anugool Lamkhum, Anirut Changphan, Nuttida Dangsuwan, Pongsatorn Chingchai","doi":"10.1177/10781552261442117","DOIUrl":"https://doi.org/10.1177/10781552261442117","url":null,"abstract":"<p><p>Irinotecan-based chemotherapy regimens are mainstay treatments for various solid tumors but are frequently complicated by acute toxicities that can impair treatment adherence and clinical outcomes. Personalized risk prediction is essential to optimize patient tolerance and safety. This study sought to develop and validate the CyFRASS-TR model, a clinical predictive tool designed to identify patients at high risk of acute irinotecan-induced toxicity, thereby enabling personalized preventative interventions. A retrospective cohort study was conducted on 429 patients with solid tumors treated with irinotecan at a single cancer center. Multivariable logistic regression was utilized for model construction, followed by rigorous internal validation via cross-validation procedures. The CyFRASS-TR scoring model demonstrated robust discriminatory capacity with an area under the receiver operating characteristic curve (AUC-ROC) of 0.8923. At a 27-point cutoff, the model yielded a sensitivity of 94.23%, a specificity of 60.00%, and a negative predictive value (NPV) of 79.0%. Significant predictors included female gender, impaired renal function (eGFR <80 mL/min), elevated serum alkaline phosphatase (ALP ≥200 IU/L), primary tumor site, surgical history, chemotherapy regimen, and treatment cycle. The CyFRASS-TR model serves as an effective screening tool for identifying high-risk patients, facilitating targeted supportive care such as atropine premedication, particularly in clinical environments where genetic testing is unavailable.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261442117"},"PeriodicalIF":0.9,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147674329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective analysis of inotuzumab-associated hepatotoxicity in adult patients with B-cell acute lymphoblastic leukemia: Expanding the Spectrum of calicheamicin syndrome.","authors":"Derek Tai, Kareem Latif, Jasmine Cha, Nidhi Kejriwal, Pranati Shah, Karina Basmajian, Daniel Park, Priscilla Soria, Kum-Ja Lee, Mojtaba Akhtari","doi":"10.1177/10781552261441537","DOIUrl":"https://doi.org/10.1177/10781552261441537","url":null,"abstract":"<p><p>BackgroundInotuzumab ozogamicin (InO), a CD22-directed antibody-drug conjugate, is effective in relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), but hepatotoxicity remains a recognized adverse effect, most commonly sinusoidal obstruction syndrome (SOS). We previously described a distinct hepatotoxic pattern characterized by recent InO exposure, elevated liver function tests (LFTs), thrombocytopenia, and abnormal hepatic imaging, with biopsy demonstrating hepatic sinusoidal congestion (HSC) without venular occlusion. We termed this entity Calicheamicin Syndrome. This study expands upon that work through a retrospective cohort analysis.MethodsAdult patients with R/R B-ALL treated with InO between 2018 and 2024 were retrospectively reviewed. Hepatotoxicity was defined as AST, ALT, ALP, or total bilirubin ≥2× the upper limit of normal within 30 days of InO administration. Patients were stratified by liver biopsy status, laboratory trends, clinical features, and imaging findings.ResultsAmong 21 patients treated with InO, all developed LFT abnormalities, with peak values occurring a median of 16 days after the final dose. Six patients (28.6%) underwent liver biopsy, all demonstrating HSC without features of SOS. Biopsied patients experienced significantly deeper thrombocytopenia (median platelet nadir 26 × 10⁹/l vs. 80 × 10⁹/l; p = 0.03), while ALP elevations were similar between groups. Median time to hepatotoxicity improvement after InO discontinuation was 18 days, and no patients progressed to SOS.ConclusionCalicheamicin Syndrome represents a reproducible and reversible hepatotoxic entity distinct from SOS, characterized by InO exposure, transaminitis, thrombocytopenia, abnormal hepatic imaging, and HSC on pathology. Early recognition may facilitate monitoring and prevent progression to severe hepatic injury.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261441537"},"PeriodicalIF":0.9,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147645656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changing trends in androgen deprivation therapy prescribing for prostate cancer in England, 2015-2024.","authors":"Gayasha Somathilake, Christopher Wood, Colm Andrews, Jonathan Aning, Jo Armes, Elizabeth Ford, Robert Kerrison, Brian MacKenna, Amir Mehrkar, Mary Rehman, Alex Walker, Agnieszka Lemanska","doi":"10.1177/10781552261436698","DOIUrl":"https://doi.org/10.1177/10781552261436698","url":null,"abstract":"<p><p>IntroductionGonadotropin-releasing hormone (GnRH) agonists are the most commonly used form of androgen deprivation therapy (ADT) for advanced prostate cancer, often prescribed with radiotherapy or chemotherapy. This study examined national trends in the prescribing of injectable GnRH agonists in England from 2015 to 2024, by formulation type and demographic factors (age, ethnicity, and deprivation). We hypothesised that the use of longer-acting formulations has been increasing over time, specifically during the COVID-19 pandemic when access to face-to-face appointments was limited, and that variation over time and by demographics could inform future service delivery.MethodsWith the approval of NHS England, we conducted a cohort study using the OpenSAFELY-TPP database of 24 million adults. Monthly prescription counts and rates (per 100,000 men with prostate cancer) were visualised over time. Generalised linear models were used to estimate the impact of the COVID-19 pandemic.ResultsThe cohort included 390,265 men with prostate cancer (mean age 69.8 years, SD 13.5). Overall, 1,535,725 prescriptions were issued to 208,010 participants (53%). Monthly prescription counts increased by 40%, from 11,787 in 2015 to 16,697 in 2024, while rates declined from 8453 to 7721. During 2020-2021, prescribing of 1- and 3-monthly formulations decreased, whereas 6-monthly formulations increased from 437 per month (245 per 100,000 men) in 2019 to 755 (349 per 100,000 men) in 2024, an excess of 29%.ConclusionsBefore the pandemic, 6-monthly formulations were rarely prescribed. Their uptake during the pandemic suggested a shift towards longer-acting formulations, reducing treatment burden. Declining GnRH rates may reflect earlier diagnosis and evolving treatment guidelines. Divergence between prescription counts and rates, and variation by demographic factors, reflected challenges faced by healthcare systems.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261436698"},"PeriodicalIF":0.9,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147638881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stability challenges of oncological medicines: The overlooked role of industrial pharmacy.","authors":"Ali Cherif Chefchaouni, Ismail Bennani, Soumaya El Baraka, Jean Marie Ouedraogo, Nihal Bhirich, Ghita Meknassi Salime, Yassir El Alaoui, Fatima-Zahra Bendadi, Soufiane El Marrakchi, Badreddine Moukafih, Younes Rahali, Abdeslam El Kartouti","doi":"10.1177/10781552261439670","DOIUrl":"https://doi.org/10.1177/10781552261439670","url":null,"abstract":"<p><p>BackgroundEnsuring the stability and quality of oncological medicines remains a major challenge across both industrial and hospital settings. These products are often biologics or highly sensitive compounds are vulnerable to chemical, physical, and microbiological degradation pathways that can compromise therapeutic efficacy and patient safety.ObjectiveThis review provides an overview of the main stability challenges associated with oncological medicines and highlights the complementary roles of industrial pharmacy and hospital pharmacy in preventing degradation, contamination, and handling-related risks.DiscussionChemical degradation mechanisms including oxidation, deamidation, acylation, and photo-induced reactions are particularly prominent in peptides, monoclonal antibodies, and antibody-drug conjugates. Physical instability, driven by temperature fluctuations or hydrophobic payloads in ADCs (, can promote aggregation and reduce shelf-life. Microbiological instability remains a critical concern, especially in immunocompromised patients, and underscores the importance of controlled environments, aseptic technique, and compliance with sterility and endotoxin standards. Contamination risks particulate, microbiological, or cross-contamination are markedly lower when oncological medicines are prepared in ISO-classified clean rooms, isolators, or closed-system transfer devices (CSTDs). Post-reconstitution stability is equally dependent on strict cold-chain management, appropriate conditioning, and optimized clinical workflows. Robotic compounding systems further enhance safety by improving precision, reducing environmental exposure, and strengthening traceability.ConclusionStability preservation for oncological medicines requires an integrated approach that bridges industrial formulation strategies, advanced manufacturing technologies, and rigorously controlled hospital practices. Strengthening the collaboration between industry and clinical pharmacy is essential to ensure the quality, safety, and therapeutic performance of anticancer treatments.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261439670"},"PeriodicalIF":0.9,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147623328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-related problems among pediatric patients with cancer admitted to the pediatric haemato-oncology department: A prospective observational study.","authors":"Nabin Pathak, Bijaya Basyal, Shreya Dhungana, Aman Kumar Sah, Rajeev Shrestha, Sunil Shrestha, Anjali Pandit, Puskar Kunwor, Renu Karki","doi":"10.1177/10781552261437734","DOIUrl":"https://doi.org/10.1177/10781552261437734","url":null,"abstract":"<p><p>BackgroundPediatric patients undergoing chemotherapy often need to take multiple medications. Consequently, they may experience drug-related problems (DRPs), including adverse drug reactions, drug interactions, and various medication errors.MethodsA prospective observational study was conducted over three months in the Pediatric Haemato-oncology department of a cancer specialty hospital of Nepal following ethical approval. DRPs were identified from patient medical records and the literature and, recorded according to the Pharmaceutical Care Network Europe V9.1 tool. Data were collected and analyzed using IBM SPSS Statistics V20 and Microsoft Excel 2013 to present the findings.ResultsAmong the 30 enrolled patients, 211 DRPs were identified in 28 patients (93.3%), averaging 7.5 DRPs per patient, all validated through case-by-case review. Treatment safety was the predominant DRP type (n = 131; 62.09%), followed by treatment ineffectiveness (n = 79; 37.44%). Drug selection (n = 116; 51.76%) and dispensing issues (n = 51; 22.77%) were the leading causes, with anti-infective drugs (n = 41; 35%) and antineoplastic agents (n = 24; 20.5%) most frequently implicated.ConclusionDRPs were prevalent among pediatric patients with cancer, with treatment safety being the most significant issue and drug selection being the primary cause. Anti-infective drugs were most frequently involved in DRPs, followed by antineoplastic and immunomodulating agents.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261437734"},"PeriodicalIF":0.9,"publicationDate":"2026-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147616057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time-saving impact of two generation model chemotherapy compounding robots on pharmacists' daily workflow: A long-term evaluation.","authors":"Yuki Tonogai, Masahiro Kondo, Yasuhiro Horita, Yuji Hotta, Yoko Furukawa-Hibi","doi":"10.1177/10781552261424178","DOIUrl":"https://doi.org/10.1177/10781552261424178","url":null,"abstract":"<p><p>IntroductionEnhancing the efficiency of anticancer drug preparation enables pharmacists to dedicate more time to providing pharmaceutical care. Although chemotherapy compounding robots are globally widespread, their long-term quantitative impact on pharmacists' daily workflow remains unclear. This study aimed to evaluate the time-saving effects of two robots, CytoCare^® and the newer ChemoRo^TM.MethodsThe time-saving effect was defined as the difference in pharmacist-involved time (the total time a pharmacist spends on a single prescription) between the assumed manual process and actual combined manual and robotic preparation process. Based on our data, these times were considered to be 9.4 and 2.0 min per prescription, respectively. We also examined robotic accuracy and compounding time to identify factors related to the time-saving effects.ResultsDuring two separate 3.5-year periods, CytoCare and ChemoRo handled 22.1% (14,021/63,464) and 44.9% (42,594/94,913) of all drug preparations, respectively. The median pharmacist-involved time saved per day was approximately 2.5 h with CytoCare and 6.5 h with ChemoRo. Furthermore, ChemoRo exhibited significantly higher accuracy, with the incidence of deviation from the true value exceeding ±5.0% being 0.16% compared to 1.34% for CytoCare (<i>P</i> < 0.001). The compounding times for both robots were similar.ConclusionsThis is the first study to demonstrate that two robots from different generations provide significant, long-term time-saving effects on pharmacists' workflow. The effect with a currently available anticancer robot, ChemoRo, is estimated to create approximately 0.8 full-time equivalents. Thus, their implementation in anticancer drug preparation will be increasingly vital for advancing pharmacist work efficiency and productivity.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261424178"},"PeriodicalIF":0.9,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variability of busulfan area under the concentration-time curve in children with different hematologic disorders.","authors":"Jie Deng, Hui Li, Zhen Peng, Jing Liu, Jie Lin, Shixi Xu, Anfa Wang, Jingyu Wang, Guangting Zeng","doi":"10.1177/10781552261424402","DOIUrl":"https://doi.org/10.1177/10781552261424402","url":null,"abstract":"<p><p>PurposeLimited data on the effect of hematologic disorders on the busulfan (Bu) pharmacokinetics in children undergoing allogeneic hematopoietic stem cell transplantation (HSCT) is available to date. This study aimed to investigate pharmacokinetic characteristics after the first Bu infusion in children with different hematologic disorders.MethodsA total of 172 Bu concentrations from 43 patients with HSCT and their demographics and characteristics were included to investigate the correlations between different hematologic disorders and Bu concentration or area under the concentration time curve (AUC) using univariate and multivariate regression analysis.ResultsBu concentration and AUC after the first dose were significantly higher in patients with leukemia than in patients with non-malignant hematologic disorders (NMHD) (<i>P</i> < 0.001). A high variability was observed with 14 (53.8%) of Bu AUC lower than 900 µM × min (3.69 mg × h/L) in patients with NMHD and 15 (88.2%) of Bu AUC higher than 1350 µM × min (5.54 mg × h/L) in patients with leukemia. In univariate analysis, concomitant use of glucocorticoids affected Bu AUC (<i>P</i> < 0.001). The Bu AUC was significantly correlated with alanine transaminase (<i>P</i> = 0.004), total bile acids (<i>P</i> = 0.003) and total bilirubin (<i>P</i> < 0.001). However, hematologic disorders was the only independent influencing factor of Bu AUC variation, after adjusting for the above variables.ConclusionVariability in Bu AUC was related to hematologic disorders of children with HSCT, which requires therapeutic drug monitoring and dose adjustment. Different phenotypes of patients should be considered when developing individualized Bu dosing regimen.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261424402"},"PeriodicalIF":0.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One patient, one order? analyzing prescription volume in oncology opioid stewardship.","authors":"Rashad Ismayilov","doi":"10.1177/10781552261420765","DOIUrl":"10.1177/10781552261420765","url":null,"abstract":"","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"590-591"},"PeriodicalIF":0.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146142806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real world comparison of filgrastim to filgrastim-sndz in patients with chemotherapy-induced neutropenia.","authors":"Manal Saad, Kelsey Shadick, Sapna Prasad, Kejal Amin, Randa Chaar, Osama Abdelghany","doi":"10.1177/10781552241290437","DOIUrl":"10.1177/10781552241290437","url":null,"abstract":"<p><p>IntroductionThere exists some apprehension by prescribers, healthcare providers, and other stakeholders regarding the real-world safety and effectiveness of biosimilars. While some of the apprehension is likely due to clinician knowledge gaps in the biosimilarity exercise, additional data (including those generated from the real-world) regarding safety and efficacy could reduce a clinician's perception of biosimilar uncertainty and can potentially increase biosimilar acceptance and uptake. The published literature is lacking regarding the real-world impact on healthcare costs and clinical outcomes when a single healthcare institution converts from filgrastim to filgrastim-sndz as its short-acting Granulocyte Colony Stimulating Factor (GCSF), especially within diverse populations and indications not explicitly studied through the registration trials. Specifically, both filgrastim and filgrastim-sndz possess FDA-approved indications within patients with hematologic malignancies receiving high-dose chemotherapy and in those undergoing bone marrow transplantation. As a biosimilar to filgrastim, the FDA did not require prospective, randomized controlled trials to obtain these indications for filgrastim-sndz. The purpose of this study is to describe real-world healthcare resource costs, utilization patterns, and clinical outcomes in patients with hematologic malignancies who received filgrastim-sndz or filgrastim to support neutrophil recovery following chemotherapy (i.e., induction or consolidation) or a bone marrow transplant (BMT) at Yale New Haven Hospital (YNHH).MethodsA total of 148 patients were identified and met the following criteria: at least 18 years old, Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, absence of fever or infection, newly diagnosed acute myeloid leukemia or newly post-bone marrow transplant and received filgrastim-sndz (Zarxio^®) or reference filgrastim (Neupogen^®).ResultsHealthcare resource utilization outcomes were compared between biosimilar and reference filgrastim using descriptive statistics. There were no major differences between either cohort, including duration of hospitalization, the number of overall emergency room visits and additional hospital admissions with a primary diagnosis of febrile neutropenia or neutropenia within 30 days post-discharge from initial hospital admission, time to neutrophil recovery following GCSF support, and the incidence and duration of both fever and febrile neutropenia. The total cost based on treatment of all patients in each arm differed significantly with filgrastim-sndz being the most cost-effective choice.Conclusionfilgrastim-sndz significantly reduced healthcare utilization costs compared to reference filgrastim with similar effect on absolute neutrophil count, incidence of fever, and febrile neutropenia.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"446-453"},"PeriodicalIF":0.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing medication therapy in elderly patients: The impact of medication review using STOPP and START criteria version 2.","authors":"Silpa Murali, Aswin Damodaran, Namita Maria Jacob, Anjaly Venugopal, Joveena Johnson, Meenu Vijayan, K Pavithran, M Sonal Sekhar","doi":"10.1177/10781552241296882","DOIUrl":"10.1177/10781552241296882","url":null,"abstract":"<p><p><b>Background:</b> Higher prevalence of inappropriate medication use among cancer patients increases risk of drug-related problems(DRP) like drug-drug interactions, ADR, and non-adherence. Potentially inappropriate medication (PIM) and Potential Prescription Omission (PPO) were identified using Screening Tool of Older Person's Prescriptions (STOPP) and Screening Tool to Alert Doctors to the Right Treatment (START) criteria. <b>Objectives:</b> The study objective was to optimize prescriptions for the elderly by analyzing the impact of medication review. <b>Methods:</b> An observational study in which PIM and/or PPO were identified and the prescriptions were optimized by a physician. <b>Results:</b> Out of 150 patients, a total of 35 drugs were stopped and 12 drugs were started. Medication omissions were identified in 12 patients (8%). There were no DRPs associated with medication adjustments. <b>Conclusion:</b> Based on a pharmacist-led comprehensive medication review of the elderly, the STOPP and START criteria allow the optimization of prescriptions.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"498-506"},"PeriodicalIF":0.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}